Botulinum toxin A treatment in toddlers with cerebral palsy

Area of Science:

• Pediatric Neurology
• Rehabilitation Medicine
• Movement Disorders

Background:

• Cerebral palsy (CP) is a common neurodevelopmental disorder affecting muscle tone and movement.
• Spastic CP, characterized by increased muscle tone, often leads to contractures and gait abnormalities in young children.
• Botulinum toxin A (BoNT-A) is a potential therapeutic agent for managing spasticity in CP.

Purpose of the Study:

• To investigate the efficacy of BoNT-A treatment in conjunction with stretching for young children with spastic CP.
• To assess the impact of BoNT-A on muscle tone, contracture development, and gait patterns.
• To evaluate long-term outcomes of early BoNT-A intervention in pediatric CP.

Main Methods:

• A randomized controlled study involving 15 infants with spastic CP (mean age 16 months).
• Participants received daily stretching; the intervention group received two BoNT-A injections in the gastrocnemius muscle 6 months apart.
• Outcomes including muscle tone, range of motion (ROM), gait analysis, GMFM-66, and PEDI were assessed over 3.5 years, with gait analysis at 5 years.

Main Results:

• BoNT-A treatment significantly reduced plantarflexor muscle tone after 3.5 years compared to controls.
• A significant increase in knee-flexion muscle tone difference was observed between groups at 3.5 years.
• Knee joint ROM increased significantly at 1 year in the BoNT-A group, while controls showed reduced ROM at knee and ankle joints after 3.5 years.

Conclusions:

• Early BoNT-A intervention, combined with stretching, may effectively decrease muscle tone and slow contracture development in children with spastic CP.
• The study found no significant group differences in gait analysis, GMFM-66, or PEDI scores.
• The long-term effects of BoNT-A on gait development in this population remain inconclusive and warrant further research.